Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
DiaMedica Logo
DiaMedica Growth Score
43
CB Rank
63694
Heat Score
60
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke.
Founded
obfuscation
PublicPost-IPO Equity Minneapolis, Minnesota, United States11-50 www.diamedica.com/
Biopharma
Biotechnology
Health Care
Therapeutics
Overview

DiaMedica
Total Funding
obfuscation
Growth Score
43
Heat Score
60

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score43
-27 pts
in past quarter
Heat Score 60
5 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About DiaMedica

CB Rank
63694
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke.
Founded
obfuscation
PublicPost-IPO Equity Minneapolis, Minnesota, United States11-50 www.diamedica.com/
Biopharma
Biotechnology
Health Care
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name DiaMedica Therapeutics, Inc.
Also Known As DiaMedica Therapeutics
Operating Status Active
Stock Symbol  NASDAQ:DMAC
Company Type For Profit
Founders  Wayne Lautt
About the Company
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke and other vascular diseases where no current therapies are available. The company's treatments primarily focus on on chronic kidney disease and acute ischemic stroke. Its pipeline product, DM199, is a recombinant form of human tissue kallikrein-1.
Phone Number (763)270-0603
Contact Email info@diamedica.com
Predictions & Insights

Growth Insight

See this Growth Insight
DiaMedica is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

DM199 (rinvecalinase alfa) for Acute Ischemic Stroke
An investigational recombinant protein therapy intended to restore KLK1 levels to improve blood flow and reduce brain tissue damage after acute ischemic stroke.
DM199 (rinvecalinase alfa) for Preeclampsia
An investigational recombinant protein therapy intended to restore KLK1 levels to improve blood flow, reduce blood pressure, and support vascular health in preeclampsia patients.

Research & Development

DiaMedica is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 14
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
3
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
3
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
3
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
3
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
3
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 14
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
3
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
3
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
3
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
3
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
3
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Trill Impact Logo
Trill Impact
—
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
—
Trill Impact Logo
Trill Impact
—
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
—
Trill Impact Logo
Trill Impact
—
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
—
Trill Impact Logo
Trill Impact
—
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
—
Trill Impact Logo
Trill Impact
—
Post-IPO Equity - DiaMedica Logo
Post-IPO Equity - DiaMedica
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 6 Contacts 29

Employee Profiles

News

News and Press

News•Jun 23, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 23, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 23, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 16, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,117
30.49%
 in past month

IT Spend

$485.8KThis year, DiaMedica is projected to spend $485.8K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Chicago, Illinois Logo
Chicago, Illinois
100
Hedging Platform Logo
Hedging Platform
100
City Stamp Works Logo
City Stamp Works
88

Actively Used Products

15DiaMedica uses 15 technology products and services including HTML5, Vimeo, and  Microsoft Outlook, according to G2 Stack.

Active Website Tech Count

22DiaMedica is actively using 22 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and  SSL by Default.
Sub-Organizations
Frequently Asked Questions

Where is DiaMedica's headquarters? DiaMedica is located in Minneapolis, Minnesota, United States.Who invested in DiaMedica? DiaMedica has 7 investors including Trill Impact and  Richard Jacinto II.When was the last funding round for DiaMedica? DiaMedica closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are DiaMedica's competitors? Alternatives and possible competitors to DiaMedica may include Comanche Biopharma, Stream Biomedical, and  Astrocyte Pharmaceuticals.How much funding has DiaMedica raised to date? DiaMedica has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(8fe006b 1)
|